EH216 Completes Demo Flight Tour in 4 Japanese Cities to Mark 1,000-Day Countdown of Expo 2025 Osaka, Kansai
July 22, 2022 08:38 ET
|
EHang Holdings Limited
GUANGZHOU, China, July 22, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world's leading autonomous aerial vehicle (“AAV”) technology platform company,...
New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B
July 21, 2022 07:00 ET
|
Freeline Therapeutics
LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the New England Journal of Medicine (NEJM) published positive data that expand upon...
Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilities
July 19, 2022 08:00 ET
|
Frontera Therapeutics
FDA clears Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a rare inherited eye disease leading to severe visual impairment that may...
Freeline Announces June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022 16:01 ET
|
Freeline Therapeutics
LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on June 30, 2022, the Company granted a newly hired employee non-statutory options to...
EHang Announced Strategic Partnership with Agricultural Bank of China Guangzhou Branch with Indicative Facilities of RMB1 Billion for Long-Term Cooperation
June 28, 2022 08:11 ET
|
EHang Holdings Limited
GUANGZHOU, China, June 28, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress
June 24, 2022 09:32 ET
|
Freeline Therapeutics
LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene...
EHang Partners with Tianxingjian on Scenic Flight Project with EH216 AAVs at Aizhai Wonder Tourist Area in Jishou, Hunan, China
June 21, 2022 09:17 ET
|
EHang Holdings Limited
GUANGZHOU, China, June 21, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B
June 14, 2022 07:00 ET
|
Freeline Therapeutics
Initial cohort one data suggest predictable and sustained Factor IX normalization, supporting additional dosing at the same low dose with the same optimized, prophylactic immune management regimen ...
Freeline Announces May 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2022 16:02 ET
|
Freeline Therapeutics
LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on May 31, 2022, the Company granted its newly hired Chief Financial Officer, Paul...
Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
June 03, 2022 16:01 ET
|
Freeline Therapeutics
LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today disclosed the receipt of a notice (the “Notice”) on May 31, 2022 from...